LEADER 01585nam  2200421Ka 450 
001 9910697589903321
005 20081002151833.0
035   $a(CKB)5470000002389050
035   $a(OCoLC)247957315
035   $a(EXLCZ)995470000002389050
100   $a20080911d2006      ua             0
101 0 $aeng
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPersistence in Medicare prescription drug expenditures by treatment class$b[electronic resource] /$fJessica S. Banthin and Edward Miller
210  1$a[Gaithersburg, Md.] :$c[Agency for Healthcare Research and Quality],$d[2006]
215   $a26 pages, 9 unnumbered pages $cdigital, PDF file
225 1 $aAgency for Healthcare Research and Quality working paper ;$vno. 06006
300   $aTitle from title screen (viewed on Sept. 11, 2008).
300   $a"September 2006."
606   $aPharmaceutical services insurance$zUnited States
606   $aMedicare
606   $aPrescription pricing$zUnited States
606   $aMedical care, Cost of$zUnited States
615  0$aPharmaceutical services insurance
615  0$aMedicare.
615  0$aPrescription pricing
615  0$aMedical care, Cost of
700   $aBanthin$b Jessica S$01399465
701   $aMiller$b G. Edward$01397112
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910697589903321
996   $aPersistence in Medicare prescription drug expenditures by treatment class$93491516
997   $aUNINA